Evidence map›Paper›PMID 38904713›Full record

ReviewPharmacological reports : PR2024

Luteolin for neurodegenerative diseases: a review.

Dunuvilla Kavindi Jayawickreme, Cletus Ekwosi, Apurva Anand, Marta Andres-Mach, Piotr Wlaź, Katarzyna Socała

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacological reports : PR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Natural Molecules for Brain Health and Resilience.International journal of molecular sciences · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dunuvilla Kavindi JayawickremeFaculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland.
Cletus EkwosiFaculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland.
Apurva AnandFaculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland.
Marta Andres-MachDepartment of Experimental Pharmacology, Institute of Rural Health, Jaczewskiego 2, Lublin, 20-950, Poland.ORCID http://orcid.org/0000-0003-4107-9184
Piotr WlaźDepartment of Animal Physiology and Pharmacology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland.ORCID http://orcid.org/0000-0002-5389-0241
Katarzyna SocałaDepartment of Animal Physiology and Pharmacology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland. katarzyna.socala@mail.umcs.pl.ORCID http://orcid.org/0000-0001-7706-2080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and multiple sclerosis affect millions of people around the world. In addition to age, which is a key factor contributing to the development of all neurodegenerative diseases, genetic and environmental components are also important risk factors. Current methods of treating neurodegenerative diseases are mostly symptomatic and do not eliminate the cause of the disease. Many studies focus on searching for natural substances with neuroprotective properties that could be used as an adjuvant therapy in the inhibition of the neurodegeneration process. These compounds include flavonoids, such as luteolin, showing significant anti-inflammatory, antioxidant, and neuroprotective activity. Increasing evidence suggests that luteolin may confer protection against neurodegeneration. In this review, we summarize the scientific reports from preclinical in vitro and in vivo studies regarding the beneficial effects of luteolin in neurodegenerative diseases. Luteolin was studied most extensively in various models of Alzheimer's disease but there are also several reports showing its neuroprotective effects in models of Parkinson's disease. Though very limited, studies on possible protective effects of luteolin against Huntington's disease and multiple sclerosis are also discussed here. Overall, although preclinical studies show the potential benefits of luteolin in neurodegenerative disorders, clinical evidence on its therapeutic efficacy is still deficient.

Indexed as

LuteolinNeurodegenerative DiseasesNeuroprotective AgentsAnimalsAntioxidantsHumansAntioxidantsLuteolinNeuroprotective AgentsApoptosisBeta amyloidCognitive dysfunctionLearning and memory impairmentNeuronal lossParkinsonismPolyphenols

Identifiers

PMID38904713
PMCPMC11294387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.